Last edition
News about "Qilu Pharmaceutical"
Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market
Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.
Qilu Pharmaceutical | 04/09/2026 | By News Bureau | 100
Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market
Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.
Qilu Pharmaceutical | 04/09/2026 | By News Bureau | 100
Biocytogen Signs Non-Exclusive VHH Antibody Licensing Deal with Qilu Pharmaceutical
Biocytogen grants Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule developed through its RenNano platform to support neuroscience drug research.
Qilu Pharmaceutical | 04/09/2026 | By News Bureau | 118
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Qilu Pharmaceutical | 28/01/2026 | By News Bureau | 214
European Commission approves EYLUXVI (ALT-L9) by Alteogen
EYLUXVI is the second biosimilar approved by the European Commission for Alteogen, following the launch of the Herceptin biosimilar in China through its partner Qilu Pharmaceutical.
Qilu Pharmaceutical | 18/09/2025 | By Dineshwori | 221
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy